Abstract
Two articles1,2 published in The Lancet in 2009 on roflumilast for chronic obstructive pulmonary disease (COPD) describe four clinical studies (M2-124, M2-125, M2-127, and M2-128) done by the drug company that owns the patent on roflumilast. The raw data on the condition of patients who participated in the studies is not available to anyone outside of the company or the US Food and Drug Administration (FDA). Since roflumilast was approved by the FDA, new information about the side-effects has come to light, from independent analysis of these data by FDA staff physicians.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
